Reduction of Wound Angiogenesis in Patients Treated with BMS-275291, a Broad Spectrum Matrix Metalloproteinase Inhibitor

• Published in: Clinical cancer research Vol. 9; no. 2; pp. 586 - 593
• Main Authors: LOCKHART, A. Craig, BRAUN, Rod D, GRICHNIK, James M, PROIA, Alan D, CONWAY, Delina A, HURWITZ, Herbert I, DAOHAI YU, ROSS, Joel R, DEWHIRST, Mark W, HUMPHREY, Jeffrey S, THOMPSON, Seth, WILLIAMS, Kathleen M, KLITZMAN, Bruce, FAN YUAN
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.02.2003
• Subjects: Antineoplastic agents; Antineoplastic Agents - adverse effects; Biological and medical sciences; Biopsy; Chemotherapy; Humans; Imidazoles; Matrix Metalloproteinase Inhibitors; Medical sciences; Neoplasms - blood supply; Neoplasms - drug therapy; Neoplasms - mortality; Neoplasms - pathology; Neovascularization, Pathologic - prevention & control; Organic Chemicals; Pharmacology. Drug treatments; Survival Analysis; Time Factors; Antineoplastic agent; Human; Solid tumor; Enzyme; Treatment efficiency; Oral administration; Enzyme inhibitor; Metalloendopeptidases; Malignant tumor; Wound; Peptidases; Angiogenesis; Chemotherapy; Treatment; Investigation method; Phase I trial; Hydrolases; Neovascularization; Antiangiogenic agent; Detection

Purpose: The purpose of this study was to evaluate the feasibility of incorporating a novel wound angiogenesis assay into a Phase I study of BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor, and to determine whether the wound angiogenesis assay was able to detect the inhibition of ang...